Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) experienced a notable 10% uptick in its stock price on Tuesday, sparked by mixed results from its Phase 3 SENTRY trial involving a combination therapy for frontline myelofibrosis patients. The study investigated the efficacy of selinexor paired with ruxolitinib.

The trial successfully hit one of its main targets, demonstrating a clear statistical advantage in reducing spleen volume. However, it fell short on the second key endpoint measuring symptom relief, which showed similar improvement levels between the combination therapy and ruxolitinib alone.

With 353 patients enrolled and randomized 2:1 to receive either selinexor plus ruxolitinib or placebo plus ruxolitinib, the latest data at the 24-week mark reported that half the patients on the combination therapy achieved the benchmark 35% or more spleen volume reduction compared to 28% with just ruxolitinib. Symptom score changes, however, were slightly better in the control group-9.89 points improvement vs. 10.86 points in the placebo arm-though not statistically meaningful.

A silver lining surfaced with overall survival outcomes, where the combination treatment showed a hazard ratio of 0.43 versus ruxolitinib only. These encouraging survival signals are being closely monitored as the trial data matures.

Exploratory findings hinted at possible disease-modifying effects; 32% of patients receiving the combination therapy saw at least a 20% reduction in variant allele frequency at week 24, compared to 24% in the ruxolitinib-alone group, pointing toward molecular responses worth further analysis.

Safety data indicated that the combo regimen maintained a manageable profile, with no unexpected adverse events reported. The most frequent side effects observed included thrombocytopenia (59%), anemia (57%), and nausea (57%) among those treated with the dual therapy.

Looking ahead, Karyopharm intends to engage with the U.S. Food and Drug Administration to discuss regulatory pathways and the possibility of filing a supplemental new drug application based on these findings. Concurrently, the company announced a private placement deal with RA Capital Management, which is projected to generate around $30 million in gross proceeds.

While the Phase 3 results present a mixed bag of clinical benefits and challenges, the stock's 10% gain reflects investor interest around potential survival benefits and disease impact signals. Whether the focus shifts primarily to these survival metrics and longer-term implications remains to be seen as the data evolves.